Proof of use and proof of injury: the records that qualify a mass tort claim

Public Radio East reported on August 13, 2026 that the Navy found 88 percent of more than 408,000 Camp Lejeune administrative claims lacked the documentation required for Justice Department review, alongside 3,773 active federal lawsuits. A mass tort claim cannot qualify on an intake narrative alone. It requires two distinct evidentiary files on paper: proof the claimant used the product or was present at the site, and clinical proof of a qualifying injury under docket criteria.

The May 11, 2026 joint status report showed that among Elective Option claims with three or more supporting documents submitted, over 88 percent still fell short of DOJ review standards, and less than 2 percent were cleared for settlement consideration. Depo-Provera, GLP-1, and medical device dockets apply this same two-file requirement; while the required documents differ, the underlying point of failure remains consistent.

The two files every intake needs

Proof of use establishes product exposure or geographic presence by identifying the prescribing doctor, the implanted device, or base assignment dates. Proof of injury establishes clinical diagnosis through certified diagnostic tests, pathology, or treating physician notes that match docket criteria.

Treating these requirements as a single undifferentiated records request frequently leads to deficiencies during court census reviews. A complete surgical record will still fail threshold review if it lacks the implant sticker or lot number, just as a brain MRI confirming a meningioma cannot substantiate a claim without proof the patient was administered Depo-Provera.

The Navy validation guidance reflects this division clearly. Each Camp Lejeune Justice Act claim requires documentation of at least 30 days at the base between August 1, 1953 and December 31, 1987, alongside signed and certified medical records showing a qualifying diagnosis or treatment date. Service records establish presence, while certified medical charts establish injury. Omission of either document prevents the claim from advancing to DOJ review.

How qualification usually runs

Most mass tort dockets require this sequence before a case fact sheet or settlement submission can proceed.

Checklist by docket type

The records required to clear a court census vary by litigation. The table provides an overview, followed by specific requirements for active mass torts.

Implant and device

Hernia mesh and vascular port lawsuits fail on product identification more often than on injury severity. Operative notes frequently use generic surgical descriptions, whereas the manufacturer, model, and lot number reside on the implant log and device sticker. Drugwatch's hernia mesh lawsuit guide identifies the operative report and implant sheet as essential baseline records. Without them, defendants can contest product identification.

Proof of injury in device litigation centers on the documented complication and revision history. For example, Becton Dickinson's Bard mesh settlement distributes awards across a tiered grid. Claims showing proof of implant without documented qualifying complications fall into a $2,500 base tier, whereas thoroughly documented revision surgeries can qualify for awards exceeding $100,000. That difference in payout depends directly on obtaining complete surgical charts.

Drug: Depo-Provera and GLP-1

In Depo-Provera MDL 3140, Pretrial Order No. 17 mandates contemporaneous proof of product administration alongside clinical proof of an intracranial meningioma. PTO 22 defines acceptable proof of use: records must state the plaintiff's name, administration or dispensing dates, and the specific brand or generic medication. While a subsequent court order created a narrow deficiency procedure for pre-June 2005 usage when providers certify records no longer exist, that exception serves only as a secondary measure when direct pharmacy records cannot be located.

In GLP-1 MDL 3094, the court established strict evidentiary standards for gastroparesis claims. On August 15, 2025, Judge Karen Marston ruled that plaintiffs alleging gastroparesis must substantiate the diagnosis with an objective gastric emptying study, such as gastric scintigraphy, a 13C-spirulina breath test, or a wireless motility capsule. General clinical notes describing symptoms like nausea and vomiting do not satisfy the court order. Proof of use continues to require pharmacy dispensing records naming Ozempic, Wegovy, Mounjaro, or related covered medications.

Toxic exposure: Camp Lejeune

Under the Navy's claim submission guidelines, claimants must provide government identification, documented presence of at least 30 cumulative days at the base between August 1953 and December 1987, and signed medical records showing diagnosis of a covered illness. A military discharge form (DD-214) suffices only if it explicitly records base assignment within that timeframe. Elective Option guidelines require certified medical records demonstrating diagnosis or treatment prior to August 10, 2022.

This split in record storage explains the large evidence gap noted in status filings. Base assignment documents typically reside with the National Personnel Records Center or military housing archives, whereas cancer and chronic illness records sit across VA hospitals and civilian oncology practices. Requesting records from only one facility leaves the claim packet incomplete.

Assembling complete qualification packets

An intake interview provides initial case details, but formal qualification requires corroborating documents. Legal teams must retrieve use and medical records in parallel, then verify that product exposure preceded the clinical diagnosis.

Dispensing and diagnostic records almost always reside at different facilities. A contraceptive injection log from 2003 and a neurosurgery imaging report from 2024 come from separate health systems. Similarly, Camp Lejeune military service files sit at the National Archives, while oncology charts remain in private or VA medical records departments. Insurance claims data allows retrieval teams to discover forgotten treating facilities when claimants cannot recall every provider from decades earlier.

Verifying chronological order prevents unexpected rejections. Both MDL orders and administrative guidelines require that exposure occurred before diagnosis. A prescription filled after initial diagnosis, or a military record that does not name Camp Lejeune, cannot support a recovery regardless of medical severity. LlamaLab retrieves records across multiple providers in 4 days on average, with 30 to 40 percent of electronic requests fulfilled same day, utilizing insurance claims history to identify unlisted facilities and providing itemized per-case invoices that qualify as recoverable disbursements.

The bottom line

The 88 percent deficiency rate in Camp Lejeune reflects missing documentation rather than substantive lack of merit. Court orders in Depo-Provera, GLP-1, and toxic exposure litigations establish a consistent standard: exposure and diagnosis must be substantiated by contemporaneous documentation matching forum criteria.

To keep dockets moving toward resolution, law firms should establish documentation before filing: verify the product or installation, obtain dated proof of use or presence, pull the required diagnostic test, and confirm chronology. A claim supported by complete exposure and diagnostic records can proceed directly into settlement review.

Sources: Public Radio East, Aug. 13, 2026; May 11, 2026 Camp Lejeune joint status report; Navy CLJA validation process; Navy Elective Option public guidance; Depo-Provera PTO 17; Depo-Provera PTO 22; MDL 3094 gastroparesis order, Aug. 15, 2025; Insurance Journal on the Bard mesh settlement; Drugwatch hernia mesh records guide. Retrieval timing is LlamaLab internal data from production requests.